KURA

NASDAQ HEALTHCARE

Kura Oncology Inc

$9.62

Live quote

Loading chart…

P/E Ratio—

P/B Ratio17.67

EV/EBITDA—

Debt/Equity—

ROE-575.39%

ROIC—

Revenue Growth25.24%

Gross Margin—

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.

Own KURA? Track it here.

Create a free account to add KURA to a portfolio and watch your P/L update in real time.

Custom screens, valuation models and backtesting are coming to Pro.

Create a free account